Takeda Pharmaceutical Company Limited (TAK)Healthcare | Drug Manufacturers - Specialty & Generic | Chuo, Japan | NYSE
18.03 USD
After hours: 18.49 +0.46 (2.530%) ⇧ (Aug. 28, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:49 a.m. EDT
The investment case for Takeda is currently bifurcated between a compelling income floor and a stagnant growth engine. On the income side, the 3.4% yield is attractive, yet the 80% payout ratio leaves little room for error if earnings miss again; this is a yield that rewards patience but penalizes volatility. The fundamental picture is mixed: while revenue growth is positive at 10%, the company is posting negative earnings and a negative return on equity, suggesting that top-line gains are not translating to bottom-line profitability. The balance sheet is a major concern, with debt-to-equity exceeding 73x, which limits the company's ability to aggressively invest in R&D or acquire competitors without diluting shareholders further. Technically, the stock is showing signs of life, trading above its 50-day and 200-day moving averages with a recent uptick in price action. However, the statistical forecast model offers only a moderate, barely positive signal for the next 45 days, indicating that the recent momentum may be fragile. The options market confirms this tension: traders are buying cheap insurance against a crash (deep OTM puts) while holding calls that expect a slow grind higher. This asymmetry suggests the market views the current rally as a potential trap or a temporary relief rally rather than a sustainable trend. Until the company demonstrates a path to restoring profitability and stabilizing its debt load, the long-term outlook remains neutral, despite the attractive dividend. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.085607 |
| AutoTheta | 0.092187 |
| AutoETS | 0.092232 |
| AutoARIMA | 0.092232 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 5.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.604 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-03-30 |
| Last Dividend Date | 2025-03-30 |
| Debt to Equity Ratio | 73.245 |
| Revenue per Share | 1462.7435 |
| Market Cap | 57,578,860,544 |
| Forward P/E | 34.02 |
| Beta | 0.10 |
| Profit Margins | -3.54% |
| Website | https://www.takeda.com |
As of Aug. 22, 2026, 1:49 a.m. EDT: Speculators are heavily positioned for downside protection via deep out-of-the-money puts, particularly in the January 2027 expiration where volume significantly exceeds open interest at strikes below the current price. This 'long put' positioning suggests a fear of a significant gap-down event or prolonged stagnation rather than a linear decline. Conversely, call activity is concentrated in the money, indicating a belief that the stock will trade sideways or drift upward without breaking key resistance levels immediately.
| Date | Dividend | Yield % |
|---|---|---|
| 2025-03-31 | 0.339 | 2.279758 |
| 2024-09-30 | 0.326 | 2.292546 |
| 2024-03-27 | 0.292 | 2.057787 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18931401 |
| Address1 | 1-1, Nihonbashi-Honcho 2-chome |
| All Time High | 31.29 |
| All Time Low | 12.28 |
| Ask | 18.35 |
| Ask Size | 20,800 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 2,396,510 |
| Average Daily Volume3 Month | 3,304,409 |
| Average Volume | 3,304,409 |
| Average Volume10Days | 2,396,510 |
| Beta | 0.096 |
| Bid | 18.25 |
| Bid Size | 8,500 |
| Book Value | 14.357233 |
| City | Chuo |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | Japan |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.03 |
| Current Ratio | 1.14 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 18.11 |
| Day Low | 17.96 |
| Debt To Equity | 73.245 |
| Display Name | Takeda Pharmaceutical Company |
| Dividend Date | 1,783,296,000 |
| Dividend Rate | 0.62 |
| Dividend Yield | 3.42 |
| Earnings Call Timestamp End | 1,746,698,400 |
| Earnings Call Timestamp Start | 1,746,698,400 |
| Earnings Growth | -0.098 |
| Earnings Quarterly Growth | -0.089 |
| Earnings Timestamp | 1,793,277,000 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 1,249,335,967,744 |
| Ebitda Margins | 0.27048 |
| Enterprise To Ebitda | 4.109 |
| Enterprise To Revenue | 1.111 |
| Enterprise Value | 5,133,491,503,104 |
| Eps Forward | 0.53 |
| Eps Trailing Twelve Months | -0.33 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,774,915,200 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.9716 |
| Fifty Day Average Change | 1.0584011 |
| Fifty Day Average Change Percent | 0.062363073 |
| Fifty Two Week Change Percent | 18.9314 |
| Fifty Two Week High | 18.9 |
| Fifty Two Week High Change | -0.86999893 |
| Fifty Two Week High Change Percent | -0.04603169 |
| Fifty Two Week Low | 12.99 |
| Fifty Two Week Low Change | 5.040001 |
| Fifty Two Week Low Change Percent | 0.38799083 |
| Fifty Two Week Range | 12.99 - 18.9 |
| Financial Currency | JPY |
| First Trade Date Milliseconds | 1,262,701,800,000 |
| Five Year Avg Dividend Yield | 4.53 |
| Float Shares | 3,156,674,975 |
| Forward Eps | 0.53 |
| Forward P E | 34.01887 |
| Free Cashflow | 541,443,883,008 |
| Full Exchange Name | NYSE |
| Full Time Employees | 47,029 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 18.4862 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.64468 |
| Gross Profits | 2,977,719,910,400 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00056 |
| Held Percent Institutions | 0.033010002 |
| Implied Shares Outstanding | 3,193,502,878 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://www.takeda.com/investor-information/ |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,743,379,200 |
| Last Dividend Value | 0.339 |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan. |
| Long Name | Takeda Pharmaceutical Company Limited |
| Market | us_market |
| Market Cap | 57,578,860,544 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_874540 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -163,436,003,328 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 58,234,842,020 |
| Number Of Analyst Opinions | 3 |
| Open | 18.0 |
| Operating Cashflow | 953,630,982,144 |
| Operating Margins | 0.16445999 |
| Payout Ratio | 0.8003 |
| Peg Ratio | 0.41 |
| Phone | 81 3 3278 2111 |
| Post Market Change | 0.45619965 |
| Post Market Change Percent | 2.5302253 |
| Post Market Price | 18.4862 |
| Post Market Time | 1,787,960,925 |
| Previous Close | 18.03 |
| Price Hint | 2 |
| Price To Book | 1.255813 |
| Price To Sales Trailing12 Months | 0.012465831 |
| Profit Margins | -0.035380002 |
| Quick Ratio | 0.513 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 18.11 |
| Regular Market Day Low | 17.96 |
| Regular Market Day Range | 17.96 - 18.11 |
| Regular Market Open | 18.0 |
| Regular Market Previous Close | 18.03 |
| Regular Market Price | 18.03 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 1,803,189 |
| Return On Assets | 0.02694 |
| Return On Equity | -0.02262 |
| Revenue Growth | 0.102 |
| Revenue Per Share | 1,462.7435 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,193,502,878 |
| Shares Percent Shares Out | 0.00090000004 |
| Shares Short | 2,992,883 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,817,076 |
| Short Name | Takeda Pharmaceutical Company L |
| Short Percent Of Float | 0.00090000004 |
| Short Ratio | 0.72 |
| Source Interval | 15 |
| Symbol | TAK |
| Target High Price | 22.895088 |
| Target Low Price | 20.852118 |
| Target Mean Price | 21.846273 |
| Target Median Price | 21.791618 |
| Total Cash | 460,981,993,472 |
| Total Cash Per Share | 145.853 |
| Total Debt | 5,536,499,105,792 |
| Total Revenue | 4,618,934,812,672 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 200.0 |
| Trailing Annual Dividend Yield | 11.092623 |
| Trailing Eps | -0.33 |
| Trailing Peg Ratio | 0.4103 |
| Triggerable | 1 |
| Two Hundred Day Average | 16.6365 |
| Two Hundred Day Average Change | 1.3935013 |
| Two Hundred Day Average Change Percent | 0.08376169 |
| Type Disp | Equity |
| Volume | 1,803,189 |
| Website | https://www.takeda.com |
| Zip | 103-8668 |